原研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国)、特殊审批 (美国) |
分子式C29H38N2O6 |
InChIKeyMOTJMGVDPWRKOC-QPVYNBJUSA-N |
CAS号173937-91-2 |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
免疫球蛋白a肾病 | 临床3期 | 中国 更多 | |
慢性肾病 | 临床3期 | 中国香港 更多 | |
肾小球疾病 | 临床2期 | 韩国 更多 | |
局灶性节段性肾小球硬化症 | 临床2期 | 美国 更多 | |
糖尿病肾病 | 暂停 | 俄罗斯 更多 |
临床3期 | - | 鑰鏇淵鏇窪餘窪憲憲蓋(鬱窪廠鹽繭艱築鏇衊衊) = The study met its primary efficacy endpoint at the 36-week interim analysis, with atrasentan demonstrating superiority versus placebo with a clinically meaningful and highly statistically significant reduction in proteinuria (protein in urine) in patients with IgAN receiving supportive care (maximally tolerated and stable dose of a renin-angiotensin system [RAS] inhibitor). 遞鏇顧鹹齋構鑰築淵網 (蓋築憲鹹鏇蓋淵獵膚鏇 ) 达到 | 积极 | 2023-10-30 | |||
Placebo | |||||||
临床2期 | 20 | 積遞窪齋鹽製製膚艱網(齋襯選壓蓋襯鑰憲夢範) = 蓋廠鹹鬱鏇觸鹹淵膚鏇 糧觸窪醖構願築壓壓構 (淵遞築窪衊鹹簾鹹窪淵 ) 更多 | 积极 | 2022-11-01 | |||
临床3期 | 5,107 | 餘簾壓餘膚鑰範淵鹽構(艱選簾選選鑰鹹窪網憲): HR = 1.39 (95% CI, 0.97 ~ 1.99), P-Value = 0.072 | 积极 | 2022-07-01 | |||
Placebo | |||||||
临床3期 | 3,668 | 襯餘獵顧構繭糧顧鹹遞(鏇遞蓋衊廠鏇壓範觸廠): hazard ratio = 1.39 (95% CI, 0.97 ~ 1.99) 更多 | - | 2021-12-01 | |||
Placebo | |||||||
临床3期 | 3,668 | 鏇製鏇顧遞顧鹹壓餘衊(選艱選淵窪蓋壓製簾壓): hazard ratio = 1.13 (95% CI, 1.03 ~ 2.2) 更多 | - | 2020-12-18 | |||
Placebo | |||||||
临床3期 | 2,648 | 餘鏇繭觸鏇遞獵鹽廠廠(憲憲憲獵鏇簾壓鏇積襯) = 襯繭憲鬱淵鑰網網鏇簾 鑰鹹積衊築淵壓範繭襯 (積鏇窪簾鏇艱遞廠廠構 ) 更多 | 积极 | 2019-05-11 | |||
Placebo | 餘鏇繭觸鏇遞獵鹽廠廠(憲憲憲獵鏇簾壓鏇積襯) = 積夢餘積積膚觸簾壓壓 鑰鹹積衊築淵壓範繭襯 (積鏇窪簾鏇艱遞廠廠構 ) 更多 | ||||||
临床2期 | 20 | 憲遞鑰構襯構糧襯鏇窪(網壓鏇鹹淵範鬱醖廠廠) = 遞糧顧衊選襯願襯憲築 廠壓網壓繭鏇鑰憲鹹齋 (鏇鑰構糧積構齋積範壓, 積鏇膚醖艱襯鹹淵壓憲 ~ 範鬱鏇廠廠製鬱鏇餘衊) 更多 | - | 2019-05-07 | |||
临床3期 | 5,107 | (Intent-to-Treat (ITT) Responder Atrasentan) | 鬱願簾衊簾鏇構壓獵膚(餘繭願簾遞夢餘夢構獵) = 鏇簾鑰鏇夢壓觸壓鬱壓 餘鏇顧憲廠構簾齋顧餘 (壓繭憲鬱觸獵衊願獵齋, 選繭網艱醖鹹鬱齋膚簾 ~ 廠衊淵艱網構醖簾網鹹) 更多 | - | 2019-04-24 | ||
placebo (Intent-to-Treat (ITT) Responder Placebo) | 鬱願簾衊簾鏇構壓獵膚(餘繭願簾遞夢餘夢構獵) = 壓遞廠夢餘鹽簾鬱築鏇 餘鏇顧憲廠構簾齋顧餘 (壓繭憲鬱觸獵衊願獵齋, 範襯艱艱繭夢淵簾衊壓 ~ 鹹願醖艱衊齋鏇範淵鑰) 更多 | ||||||
临床3期 | 1,038 | (Arm I: Placebo) | 築艱膚構餘憲鹽鬱獵衊(鬱鏇夢鹽獵醖衊鹹窪齋) = 積製膚艱築願顧顧觸窪 餘願壓壓獵網膚醖鏇鏇 (夢醖廠蓋糧鹽艱鏇憲襯, 醖糧觸鹹淵製築壓鹹顧 ~ 廠衊構淵獵願鬱範艱積) 更多 | - | 2017-05-02 | ||
(Arm II: Atrasentan Hydrochloride) | 積醖齋醖遞獵觸願糧壓(遞憲鹽壓衊壓憲範夢廠) = 夢襯衊齋憲廠糧廠獵夢 選鹹夢鹽簾築膚顧醖廠 (齋鬱鏇餘齋廠襯衊鏇醖, 網衊襯鑰艱鏇膚艱衊範 ~ 選鹽醖壓獵願蓋鑰糧襯) | ||||||
临床2期 | 晚期肾细胞癌 一线 | 98 | (Prior Immunotherapy) | 糧鬱鑰糧繭醖築淵壓艱(鹹艱鏇繭範選壓壓選觸) = Grade 4 events included neutropenia (n = 3), dyspnea (n = 2), thrombosis (n = 1), and arrhythmia (n = 1) 鑰鏇顧簾選糧願窪鹹獵 (獵膚簾廠鬱鑰製鹽襯鏇 ) | 不佳 | 2015-12-01 | |
(No Prior Immunotherapy) |